CO7010837A2 - Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf - Google Patents

Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf

Info

Publication number
CO7010837A2
CO7010837A2 CO14161404A CO14161404A CO7010837A2 CO 7010837 A2 CO7010837 A2 CO 7010837A2 CO 14161404 A CO14161404 A CO 14161404A CO 14161404 A CO14161404 A CO 14161404A CO 7010837 A2 CO7010837 A2 CO 7010837A2
Authority
CO
Colombia
Prior art keywords
amino
substituted
kinase inhibitors
compounds derived
raf kinase
Prior art date
Application number
CO14161404A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael J Kaufman
Phenil J Patel
Craig D Wolfangel
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7010837(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of CO7010837A2 publication Critical patent/CO7010837A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CO14161404A 2012-03-07 2014-07-24 Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf CO7010837A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
CO7010837A2 true CO7010837A2 (es) 2014-07-31

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14161404A CO7010837A2 (es) 2012-03-07 2014-07-24 Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf

Country Status (39)

Country Link
US (2) US9334267B2 (OSRAM)
EP (1) EP2850082B1 (OSRAM)
JP (1) JP2015509536A (OSRAM)
KR (1) KR20140129087A (OSRAM)
CN (1) CN104302646B (OSRAM)
AP (1) AP2014007899A0 (OSRAM)
AR (1) AR090151A1 (OSRAM)
AU (1) AU2013230146B2 (OSRAM)
BR (1) BR112014018528A8 (OSRAM)
CA (1) CA2863673A1 (OSRAM)
CL (1) CL2014002220A1 (OSRAM)
CO (1) CO7010837A2 (OSRAM)
CR (1) CR20140378A (OSRAM)
CY (1) CY1117846T1 (OSRAM)
DK (1) DK2850082T3 (OSRAM)
DO (1) DOP2014000200A (OSRAM)
EA (1) EA024824B1 (OSRAM)
EC (1) ECSP14017584A (OSRAM)
ES (1) ES2584387T3 (OSRAM)
HK (1) HK1202541A1 (OSRAM)
HR (1) HRP20160654T1 (OSRAM)
HU (1) HUE028095T2 (OSRAM)
IL (1) IL234052A (OSRAM)
IN (1) IN2014MN01575A (OSRAM)
LT (1) LT2850082T (OSRAM)
MA (1) MA37316B1 (OSRAM)
ME (1) ME02423B (OSRAM)
MX (1) MX2014010701A (OSRAM)
NZ (1) NZ627454A (OSRAM)
PE (1) PE20142338A1 (OSRAM)
PH (1) PH12014501986B1 (OSRAM)
PT (1) PT2850082T (OSRAM)
RS (1) RS54840B1 (OSRAM)
SG (1) SG11201404969YA (OSRAM)
SI (1) SI2850082T1 (OSRAM)
TN (1) TN2014000375A1 (OSRAM)
TW (1) TW201348233A (OSRAM)
UA (1) UA112340C2 (OSRAM)
WO (2) WO2013134243A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
MX2018015353A (es) * 2016-06-10 2019-09-09 Novartis Ag Usos terapeuticos de un inhibidor de c-raf.
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CN110545853A (zh) * 2017-04-28 2019-12-06 石英治疗有限公司 Raf降解偶联化合物
PE20210163A1 (es) 2017-12-21 2021-01-26 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
LT3921030T (lt) 2019-02-06 2024-01-25 Eli Lilly And Company 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
AR118119A1 (es) * 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
AU2020268814A1 (en) 2019-05-03 2021-12-16 Kinnate Biopharma Inc. Inhibitors of RAF kinases
PE20220592A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2およびperkキナーゼ阻害剤およびその使用方法
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Sos1阻害剤およびその使用
IL307908A (en) 2021-04-23 2023-12-01 Kinnate Biopharma Inc Cancer treatment with a RAF inhibitor
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
IL312905A (en) 2021-12-01 2024-07-01 Boehringer Ingelheim Int Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20240133793A (ko) 2021-12-09 2024-09-04 데시페라 파마슈티칼스, 엘엘씨. Raf 키나아제 억제제 및 그 사용 방법
US20230357179A1 (en) 2021-12-09 2023-11-09 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
US20250382288A1 (en) 2021-12-23 2025-12-18 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CA3266173A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING
AR130848A1 (es) 2022-10-26 2025-01-22 Boehringer Ingelheim Int Compuestos heterocíclicos con capacidad para activar el receptor sting
KR20250092268A (ko) 2022-10-26 2025-06-23 베링거 인겔하임 인터내셔날 게엠베하 Sting을 활성화시킬 수 있는 헤테로사이클릭 화합물
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US20250313560A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
AR080151A1 (es) * 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
RS54840B1 (sr) 2016-10-31
KR20140129087A (ko) 2014-11-06
WO2013134243A1 (en) 2013-09-12
ECSP14017584A (es) 2016-01-29
BR112014018528A8 (pt) 2017-07-11
DK2850082T3 (en) 2016-08-15
PE20142338A1 (es) 2015-01-10
IL234052A (en) 2016-05-31
AU2013230146B2 (en) 2015-09-10
EP2850082B1 (en) 2016-05-18
MX2014010701A (es) 2015-03-10
BR112014018528A2 (OSRAM) 2017-06-20
US9334267B2 (en) 2016-05-10
TN2014000375A1 (en) 2015-12-21
ES2584387T3 (es) 2016-09-27
JP2015509536A (ja) 2015-03-30
CY1117846T1 (el) 2017-05-17
IN2014MN01575A (OSRAM) 2015-05-08
LT2850082T (lt) 2016-09-12
CN104302646A (zh) 2015-01-21
SG11201404969YA (en) 2014-10-30
US8741911B2 (en) 2014-06-03
WO2013134252A1 (en) 2013-09-12
HUE028095T2 (en) 2016-11-28
TW201348233A (zh) 2013-12-01
AR090151A1 (es) 2014-10-22
CR20140378A (es) 2014-11-27
US20130252977A1 (en) 2013-09-26
SI2850082T1 (sl) 2016-07-29
UA112340C2 (uk) 2016-08-25
HK1202541A1 (en) 2015-10-02
DOP2014000200A (es) 2014-10-15
AU2013230146A1 (en) 2014-08-14
CL2014002220A1 (es) 2015-06-05
CN104302646B (zh) 2016-05-04
US20150119392A1 (en) 2015-04-30
PH12014501986A1 (en) 2014-11-24
MA37316B1 (fr) 2017-03-31
CA2863673A1 (en) 2013-09-12
PH12014501986B1 (en) 2014-11-24
NZ627454A (en) 2016-09-30
HRP20160654T1 (hr) 2016-07-01
EP2850082A1 (en) 2015-03-25
EA201491456A1 (ru) 2014-12-30
EA024824B1 (ru) 2016-10-31
PT2850082T (pt) 2016-07-15
ME02423B (me) 2016-09-20
MA37316A1 (fr) 2016-06-30
AP2014007899A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
CO7010837A2 (es) Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
AP3902A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL242285A (en) Compounds 4-methoxy-n3- (pyrimidine-2-ram) benzene-3, 1-substituted diamine and their salts
SI2857404T1 (sl) Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji
BR112013025792A2 (pt) Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
EP2922828A4 (en) SUBSTITUTED REVERSE PYRIMIDINE BMI-1 HEMMER
PL3004061T3 (pl) Związki 3,4-dihydroizochinolin-2(1h)-ylowe
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
IL242162B (en) Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
EP3096762C0 (en) PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS
CO6791612A2 (es) Piridinilo- y pirazinilo-metiloxi - arilo derivados útiles como inhibidores de tirosina quinasa del bazo (syk)
EP2886540A4 (en) BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS
SI2948443T1 (sl) Novi pirimidinski derivati kot inhibitorji fosfodiesteraze 10 (PDE-10)
TH1501001335A (th) กระบวนการที่ปรับปรุงแล้วสำหรับการเตรียมของ 2-อะมิโน-5,8-ไดเมธอกซิ[1,2,4]ไทรอะโซโล[1,5-c]ไพริมิดีนจาก 4-อะมิโน-2,5-ไดเมธอกซิไพริมิดีน
BRPI0906985A2 (pt) Derivados de pirido[4,3-d]pirimidinona como inibidores de cinase